Meta-Analysishigh evidence
Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
Lancet (London, England)·August 30, 2026·PMID 42669300
Why it mattersMany stable post-MI patients remain on β-blockers indefinitely despite uncertain benefit, exposing them to potential side effects and polypharmacy. This analysis provides robust evidence that discontinuation may be safe in selected patients without heart failure or reduced ejection fraction, potentially simplifying regimens.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled